- Grifols, S.A. (NASDAQ:GRFS) has acquired 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited.
- Financed through Grifols’ own resources, the transaction valued at $370M will not necessitate any debt issuance, the company said.
- With the acquisition which has already received regulatory clearances from the FDA and the UK’s Medicines and Healthcare Products Regulatory Agency ("MHRA"), Grifols will be able to obtain a run-rate of 1M liters of plasma per year.
- The company with 344 plasma centers worldwide including 289 in the U.S. and 55 in Europe has been able to limit its impact on net plasma supply by 15% in 2020 despite COVID-related constraints.
- Immunoglobulin therapy providers including Grifols surged in August after the FDA greenlighted the emergency use of convalescent plasma for COVID-19.